Chemistry:ATC code L01

Short description: Pharmaceutical drug classification

L01A Alkylating agents

L01AD04 Streptozocin

L01AD05 Fotemustine

L01AD06 Nimustine

L01AD07 Ranimustine

L01AD08 Uramustine

L01AG Epoxides

L01AG01 Etoglucid

L01AX Other alkylating agents

L01AX01 Mitobronitol

L01AX02 Pipobroman

L01AX03 Temozolomide

L01AX04 Dacarbazine

L01B Antimetabolites

L01BA Folic acid analogues

L01BA01 Methotrexate

L01BA03 Raltitrexed

L01BA04 Pemetrexed

L01BA05 Pralatrexate

L01BB Purine analogues

L01BB02 Mercaptopurine

L01BB03 Tioguanine

L01BB04 Cladribine

L01BB05 Fludarabine

L01BB06 Clofarabine

L01BB07 Nelarabine

QL01BB90 Rabacfosadine

L01BC Pyrimidine analogues

L01BC01 Cytarabine

L01BC02 Fluorouracil

L01BC03 Tegafur

L01BC04 Carmofur

L01BC05 Gemcitabine

L01BC06 Capecitabine

L01BC07 Azacitidine

L01BC08 Decitabine

L01BC09 Floxuridine

L01BC52 Fluorouracil, combinations

L01BC53 Tegafur, combinations

L01BC58 Decitabine, combinations

L01BC59 Trifluridine, combinations

L01C Plant alkaloids and other natural products

L01CA Vinca alkaloids and analogues

L01CA01 Vinblastine

L01CA02 Vincristine

L01CA03 Vindesine

L01CA04 Vinorelbine

L01CA05 Vinflunine

L01CA06 Vintafolide

L01CB Podophyllotoxin derivatives

L01CB01 Etoposide

L01CB02 Teniposide

L01CC Colchicine derivatives

L01CC01 Demecolcine

L01CD Taxanes

L01CD01 Paclitaxel

L01CD02 Docetaxel

L01CD03 Paclitaxel poliglumex

L01CD04 Cabazitaxel

L01CD51 Paclitaxel and encequidar

L01CE Topoisomerase 1 (TOP1) inhibitors

L01CE01 Topotecan

L01CE02 Irinotecan

L01CE03 Etirinotecan pegol

L01CE04 Belotecan

L01CX Other plant alkaloids and natural products

L01CX01 Trabectedin

L01D Cytotoxic antibiotics and related substances

L01DA Actinomycines

L01DA01 Dactinomycin

L01DB Anthracyclines and related substances

L01DB01 Doxorubicin

L01DB02 Daunorubicin

L01DB03 Epirubicin

L01DB04 Aclarubicin

L01DB05 Zorubicin

L01DB06 Idarubicin

L01DB07 Mitoxantrone

L01DB08 Pirarubicin

L01DB09 Valrubicin

L01DB10 Amrubicin

L01DB11 Pixantrone

L01DC Other cytotoxic antibiotics

L01DC01 Bleomycin

L01DC02 Plicamycin

L01DC03 Mitomycin

L01DC04 Ixabepilone

L01E Protein kinase inhibitors

L01EA BCR-ABL tyrosine kinase inhibitors

L01EA01 Imatinib

L01EA02 Dasatinib

L01EA03 Nilotinib

L01EA04 Bosutinib

L01EA05 Ponatinib

L01EA06 Asciminib

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

L01EB01 Gefitinib

L01EB02 Erlotinib

L01EB03 Afatinib

L01EB04 Osimertinib

L01EB05 Rociletinib

L01EB06 Olmutinib

L01EB07 Dacomitinib

L01EB08 Icotinib

L01EB09 Lazertinib

L01EB10 Mobocertinib

L01EB11 Aumolertinib

L01EC B-Raf serine-threonine kinase (BRAF) inhibitors

L01EC01 Vemurafenib

L01EC02 Dabrafenib

L01EC03 Encorafenib

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

L01ED01 Crizotinib

L01ED02 Ceritinib

L01ED03 Alectinib

L01ED04 Brigatinib

L01ED05 Lorlatinib

L01EE Mitogen-activated protein kinase (MEK) inhibitors

L01EE01 Trametinib

L01EE02 Cobimetinib

L01EE03 Binimetinib

L01EE04 Selumetinib

L01EF Cyclin-dependent kinase (CDK) inhibitors

L01EF01 Palbociclib

L01EF02 Ribociclib

L01EF03 Abemaciclib

L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors

L01EG01 Temsirolimus

L01EG02 Everolimus

L01EG03 Ridaforolimus

L01EG04 Sirolimus

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

L01EH01 Lapatinib

L01EH02 Neratinib

L01EH03 Tucatinib

L01EJ Janus-associated kinase (JAK) inhibitors

L01EJ01 Ruxolitinib

L01EJ02 Fedratinib

L01EJ03 Pacritinib

L01EJ04 Momelotinib

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

L01EK01 Axitinib

L01EK02 Cediranib

L01EK03 Tivozanib

L01EK04 Fruquintinib

L01EL Bruton's tyrosine kinase (BTK) inhibitors

L01EL01 Ibrutinib

L01EL02 Acalabrutinib

L01EL03 Zanubrutinib

L01EL04 Orelabrutinib

L01EL05 Pirtobrutinib

L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors

L01EM01 Idelalisib

L01EM02 Copanlisib

L01EM03 Alpelisib

L01EM04 Duvelisib

L01EM05 Parsaclisib

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

L01EN01 Erdafitinib

L01EN02 Pemigatinib

L01EN03 Infigratinib

L01EN04 Futibatinib

L01EX Other protein kinase inhibitors

L01EX01 Sunitinib

L01EX02 Sorafenib

L01EX03 Pazopanib

L01EX04 Vandetanib

L01EX05 Regorafenib

L01EX06 Masitinib

L01EX07 Cabozantinib

L01EX08 Lenvatinib

L01EX09 Nintedanib

L01EX10 Midostaurin

L01EX11 Quizartinib

L01EX12 Larotrectinib

L01EX13 Gilteritinib

L01EX14 Entrectinib

L01EX15 Pexidartinib

L01EX17 Capmatinib

L01EX18 Avapritinib

L01EX19 Ripretinib

L01EX21 Tepotinib

L01EX22 Selpercatinib

L01EX23 Pralsetinib

L01EX24 Surufatinib

L01EX25 Umbralisib

L01EX26 Sitravatinib

L01EX27 Capivasertib

QL01EX90 Toceranib

L01F Monoclonal antibodies and antibody drug conjugates

L01FA CD20 (clusters of differentiation 20) inhibitors

L01FA01 Rituximab

L01FA02 Ofatumumab

L01FA03 Obinutuzumab

L01FB CD22 (clusters of differentiation 22) inhibitors

L01FB01 Inotuzumab ozogamicin

L01FB02 Moxetumomab pasudotox

L01FC CD38 (clusters of differentiation 38) inhibitors

L01FC01 Daratumumab

L01FC02 Isatuximab

L01FD HER2 (human epidermal growth factor receptor 2) inhibitors

L01FD01 Trastuzumab

L01FD02 Pertuzumab

L01FD03 Trastuzumab emtansine

L01FD04 Trastuzumab deruxtecan

L01FD05 Trastuzumab duocarmazine

L01FD06 Margetuximab

L01FE EGFR (epidermal growth factor receptor) inhibitors

L01FE01 Cetuximab

L01FE02 Panitumumab

L01FE03 Necitumumab

L01FF PD-1/PDL-1 (programmed cell death protein 1/ death ligand 1) inhibitors

L01FF01 Nivolumab

L01FF02 Pembrolizumab

L01FF03 Durvalumab

L01FF04 Avelumab

L01FF05 Atezolizumab

L01FF06 Cemiplimab

L01FF07 Dostarlimab

L01FF08 Prolgolimab

L01FF09 Tislelizumab

L01FF10 Retifanlimab

L01FF11 Sugemalimab

L01FF12 Serplulimab

L01FF13 Toripalimab

L01FG VEGF/VEGFR (vascular endothelial growth factor) inhibitors

L01FG01 Bevacizumab

L01FG02 Ramucirumab

L01FX Other monoclonal antibodies and antibody drug conjugates

L01FX01 Edrecolomab

L01FX02 Gemtuzumab ozogamicin

L01FX03 Catumaxomab

L01FX04 Ipilimumab

L01FX05 Brentuximab vedotin

L01FX06 Dinutuximab beta

L01FX07 Blinatumomab

L01FX08 Elotuzumab

L01FX09 Mogamulizumab

L01FX10 Olaratumab

L01FX11 Bermekimab

L01FX12 Tafasitamab

L01FX13 Enfortumab vedotin

L01FX14 Polatuzumab vedotin

L01FX15 Belantamab mafodotin

L01FX16 Oportuzumab monatox

L01FX17 Sacituzumab govitecan

L01FX18 Amivantamab

L01FX19 Sabatolimab

L01FX20 Tremelimumab

L01FX21 Naxitamab

L01FX22 Loncastuximab tesirine

L01FX23 Tisotumab vedotin

L01FX24 Teclistamab

L01FX25 Mosunetuzumab

L01FX26 Mirvetuximab soravtansine

L01FX27 Epcoritamab

L01FX28 Glofitamab

L01FX29 Talquetamab

L01FY Combinations of monoclonal antibodies and antibody drug conjugates

L01FY01 Pertuzumab and trastuzumab

L01FY02 Nivolumab and relatlimab

L01FY03 Prolgolimab and nurulimab

L01X Other antineoplastic agents

L01XA Platinum compounds

L01XA01 Cisplatin

L01XA02 Carboplatin

L01XA03 Oxaliplatin

L01XA04 Satraplatin

L01XA05 Polyplatillen

L01XB Methylhydrazines

L01XB01 Procarbazine

L01XD Sensitizers used in photodynamic/radiation therapy

L01XD01 Porfimer sodium

L01XD03 Methyl aminolevulinate

L01XD04 Aminolevulinic acid

L01XD05 Temoporfin

L01XD06 Efaproxiral

L01XD07 Padeliporfin

L01XF Retinoids for cancer treatment

L01XF01 Tretinoin

L01XF02 Alitretinoin

L01XF03 Bexarotene

L01XG Proteasome inhibitors

L01XG01 Bortezomib

L01XG02 Carfilzomib

L01XG03 Ixazomib

L01XH Histone deacetylase (HDAC) inhibitors

L01XH01 Vorinostat

L01XH02 Romidepsin

L01XH03 Panobinostat

L01XH04 Belinostat

L01XH05 Entinostat

L01XJ Hedgehog pathway inhibitors

L01XJ01 Vismodegib

L01XJ02 Sonidegib

L01XJ03 Glasdegib

L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors

L01XK01 Olaparib

L01XK02 Niraparib

L01XK03 Rucaparib

L01XK04 Talazoparib

L01XK05 Veliparib

L01XK06 Pamiparib

L01XK52 Niraparib and abiraterone

L01XL Antineoplastic cell and gene therapy

L01XL01 Sitimagene ceradenovec

L01XL02 Talimogene laherparepvec

L01XL03 Axicabtagene ciloleucel

L01XL04 Tisagenlecleucel

L01XL05 Ciltacabtagene autoleucel

L01XL06 Brexucabtagene autoleucel

L01XL07 Idecabtagene vicleucel

L01XL08 Lisocabtagene maraleucel

L01XL09 Tabelecleucel

L01XL10 Nadofaragene firadenovec

L01XL11 Lifileucel

L01XX Other antineoplastic agents

L01XX01 Amsacrine

L01XX02 Asparaginase

L01XX03 Altretamine

L01XX05 Hydroxycarbamide

L01XX07 Lonidamine

L01XX08 Pentostatin

L01XX10 Masoprocol

L01XX11 Estramustine

L01XX16 Mitoguazone

L01XX18 Tiazofurine

L01XX23 Mitotane

L01XX24 Pegaspargase

L01XX27 Arsenic trioxide

L01XX29 Denileukin diftitox

L01XX33 Celecoxib

L01XX35 Anagrelide

L01XX36 Oblimersen

L01XX40 Omacetaxine mepesuccinate

L01XX41 Eribulin

L01XX44 Aflibercept

L01XX46 Olaparib

L01XX52 Venetoclax

L01XX53 Vosaroxin

L01XX57 Plitidepsin

L01XX58 Epacadostat

L01XX59 Enasidenib

L01XX62 Ivosidenib

L01XX66 Selinexor

L01XX67 Tagraxofusp

L01XX69 Lurbinectedin

L01XX72 Tazemetostat

L01XX73 Sotorasib

L01XX74 Belzutifan

L01XX75 Tebentafusp

L01XX77 Adagrasib

L01XX78 Navitoclax

L01XX79 Eflornithine

L01XX80 Imetelstat

QL01XX91 Tigilanol tiglate

QL01XX92 Verdinexor

L01XY Combinations of antineoplastic agents

L01XY01 Cytarabine and daunorubicin

References

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/ATC code L01. Read more

Anonymous

Search